Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Arcus Biosciences Inc is a biotechnology business based in the US. Arcus Biosciences shares (RCUS) are listed on the NYSE and all prices are listed in US Dollars. Arcus Biosciences employs 236 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$34.19|
|52-week range||$18.51 - $42.36|
|50-day moving average||$33.62|
|200-day moving average||$30.07|
|Wall St. target price||$53.90|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.02|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||5.17%|
|1 month (2021-09-20)||-2.62%|
|3 months (2021-07-21)||7.79%|
|6 months (2021-04-21)||0.71%|
|1 year (2020-10-21)||75.33%|
|2 years (2019-10-21)||303.18%|
|3 years (2018-10-19)||189.99%|
|5 years (2016-10-17)||N/A|
|Revenue TTM||$92.9 million|
|Gross profit TTM||$-81,831,000|
|Return on assets TTM||-18.05%|
|Return on equity TTM||-38.44%|
|Market capitalisation||$2.5 billion|
TTM: trailing 12 months
There are currently 7.1 million Arcus Biosciences shares held short by investors – that's known as Arcus Biosciences's "short interest". This figure is 7.3% down from 7.7 million last month.
There are a few different ways that this level of interest in shorting Arcus Biosciences shares can be evaluated.
Arcus Biosciences's "short interest ratio" (SIR) is the quantity of Arcus Biosciences shares currently shorted divided by the average quantity of Arcus Biosciences shares traded daily (recently around 633196.43493761). Arcus Biosciences's SIR currently stands at 11.22. In other words for every 100,000 Arcus Biosciences shares traded daily on the market, roughly 11220 shares are currently held short.
However Arcus Biosciences's short interest can also be evaluated against the total number of Arcus Biosciences shares, or, against the total number of tradable Arcus Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcus Biosciences's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Arcus Biosciences shares in existence, roughly 100 shares are currently held short) or 0.1735% of the tradable shares (for every 100,000 tradable Arcus Biosciences shares, roughly 174 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Arcus Biosciences.
Find out more about how you can short Arcus Biosciences stock.
We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $18.51 up to $42.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 1.0089. This would suggest that Arcus Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co. , Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.